Welcome to our dedicated page for Datameds AI news (Ticker: MEDS), a resource for investors and traders seeking the latest updates and insights on Datameds AI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Datameds AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Datameds AI's position in the market.
DataMeds AI (NASDAQ:MEDS) announced the U.S. direct-to-consumer launch of medical food Galectovid(TM) for the 2026 Cold & Flu Season, tied to its #Back2School50% campaign offering 50% off online at Tollo Health’s store and DataMeds’ Corexa Pharmacy store.
Galectovid is an over-the-counter medical food for the dietary management of galectin‑1 and galectin‑3 associated viral infections, categorized under section 5(b)(3) of the Orphan Drug Act, with ingredients on the FDA’s GRAS list and intended for use under physician supervision. According to DataMeds AI, effects are expected to begin within hours and the product may be used alongside other natural antiviral products as part of broader acute or chronic viral infection management.
DataMeds AI (NASDAQ:MEDS)/b) reported Q2 2026 net revenues of
The company raised $6.5 million in June 2026, restructured $14.5 million of debt and ended June with $2.46 million in cash but a stockholders’ deficit of $19.50 million. Corporate actions included a 1‑for‑50 reverse split, a July 2026 rebrand from Wellgistics Health to DataMeds AI with ticker change to MEDS, and lock‑up agreements covering about 49% of outstanding shares.
Strategically, DataMeds AI agreed to the pending “Datavault Transaction” with Datavault AI (NASDAQ:DVLT), EOS Technology Holdings and Scilex Holdings to expand its PharmacyChain license, acquire QOLPOM biometric patents and a controlling interest in Tollo Health. It plans to launch the Health Lives Here app with NFL Alumni Health in September 2026 targeting GLP‑1 patients in rural communities, supported by Corexa Health and new products such as Forzet, Tollovid and Galectovid.
DataMEDS AI (NASDAQ: MEDS) set September 9, 2026 as the Payment Date for its previously announced distribution of Dream Bowl Meme Coin I tokens to holders of common stock and other eligible equity as of the August 7, 2026 Record Date.
Record holders are entitled to 50 Dream Bowl Tokens per share of common stock (including shares issuable on conversion or exercise of eligible securities). The Board may change the Payment Date or revoke the distribution based on factors including solvency analysis. DataMEDS intends to list the tokens on the Biconomy exchange in Q3 2026. Holders are expected to open a Datavault wallet and sign an Opt-In Agreement. The tokens are described as digital collectibles for personal, non-commercial use, with no equity, dividend, or profit rights and no assurance of any value.
DataMeds AI (NASDAQ:MEDS) reported multiple developments at its Corexa Health pharmacy division, positioning Corexa Pharmacy as a key growth driver for the second half of 2026. July 2026 revenue exceeded $600,000, which the company said stabilizes an annualized run rate above $7 million.
Corexa Pharmacy registered with TrumpRx to offer patients oral and injectable GLP-1 agonist drugs, including Eli Lilly's Foundayo and Novo Nordisk's oral Wegovy, with certain oral options available for as little as $149 out-of-pocket. Companion medical foods Forzet and Galectovid, and dietary supplement Tollovid, manufactured by Tollo Health, are now available alongside other nutraceuticals.
The company launched online store CorexaRx.com/Store and integrated it into the Health Lives Here app, initially introduced for former NFL players via NFL Alumni Health, enabling telemedicine visits, GLP-1 prescriptions, product refills, and health data monitoring. According to DataMeds AI, a public launch of the Health Lives Here app is expected in September 2026 with a staged state-by-state rollout starting in North Carolina.
DataMeds AI (NASDAQ:MEDS) reported it has completed the renaming of its pharmacy and pharmacy hub subsidiaries to Corexa Pharmacy and Corexa Tech & Hub, under a newly renamed pharmacy-focused division, Corexa Health. The company’s pharmaceutical distribution subsidiary will remain Wellgistics.
According to DataMeds AI, the new Corexa Health structure is intended to separate pharmacy operations from other planned healthcare services divisions in telemedicine and diagnostic laboratories. The company also plans to expand its EinsteinRx AI platform using intellectual property licensed from DataVault AI (NASDAQ:DVLT), alongside proposed acquisitions of Tollo Health and QOLPOM-related intellectual property to support rural-focused, direct-to-consumer healthcare services.
DataMeds AI (NASDAQ: MEDS) reiterated the August 7, 2026 record date for its previously announced Dream Bowl Meme Coin dividend, confirming a 50:1 token-to-common-share ratio. The company specified that the official trading platform for Dream Bowl Meme Coin tokens is Biconomy and that the token is not authorized to trade on Coinbase.
According to DataMeds AI, the company also plans to pursue fail-to-deliver notices aggressively. The release further describes DataMeds AI’s Health IT focus, including its EinsteinRx and PharmacyChain platforms and Corexa Health pharmacy subsidiary.
DataMeds AI (NASDAQ: MEDS) announced that Interim Co-CEO Gerald Commissiong will appear in person on Fox Business’ “Claman Countdown” between 3–4 p.m. ET on August 5, 2026, alongside an NFL Hall of Famer, to introduce the “Health Lives Here” initiative developed with NFL Alumni Health (NFLAH) to improve rural healthcare access.
Health Lives Here uses a subset of subsidiary Corexa Health’s 6,500+ independent pharmacy network as local hubs, integrating the company’s Einstein AI, PharmacyChain blockchain platform, wearables, consumer apps, telemedicine, and proprietary Tollo Health medical foods and supplements to enhance patient engagement, health data control, and support for complex conditions such as Long COVID.
DataMeds AI (NASDAQ:MEDS) announced that its wholly owned online pharmacy, Corexa Pharmacy, has begun direct-to-consumer distribution of Tollo Health’s products Tollovid®, a 3CL protease inhibitor dietary supplement, and Galactovid™, a medical food for galectin-1/3 associated viral infections, via www.CorexaRx.com/Store.
Corexa Health, DataMeds AI’s pharmacy-focused subsidiary, has entered into a pharmacy-focused distribution arrangement with Tollo Health to offer these products through pharmacist-supported and Corexa-affiliated channels. DataMeds AI has also signed a non-binding letter of intent to acquire a controlling interest in Tollo Health, subject to definitive agreements and customary closing conditions, with no assurance of completion.
DataMeds AI (NASDAQ:MEDS) and Datavault AI (NASDAQ:DVLT) amended their definitive agreement to expand the PharmacyChain blockchain-related technology license from pharmaceutical distribution into all unencumbered commercial healthcare, healthspan and wellness uses of Datavault AI intellectual property. The amendment, completed ahead of a proposed multi-party business combination involving Scilex Holdings, EOS Technology Holdings’ QOLPOM patent portfolio and the acquisition of a controlling interest in Tollo Health, is intended to support the private launch of the Health Lives Here app to NFL Alumni Health members on August 6, 2026. Under the revised terms, Datavault AI will receive common shares equal to about 19.9% of DataMEDS common stock, instead of preferred shares, upon satisfaction of closing conditions, with the share value expected to be recognized as revenue by Datavault AI. DataMEDS also highlighted its recent Nasdaq listing under “MEDS” and a planned dividend of 50 Dream Bowl Meme Coin tokens per share as of an August 7, 2026 record date, subject to change at its discretion.
Datavault AI (NASDAQ: DVLT) amended its definitive agreement with DataMeds AI (NASDAQ: MEDS) to expand its PharmacyChain blockchain-related technology license from pharmaceutical distribution to all unencumbered commercial healthcare, healthspan and wellness uses of Datavault AI intellectual property. The expansion is intended to bring Datavault AI’s data monetization and real‑world asset tokenization technologies into DataMEDS’ EinsteinRX platform and broader healthcare data environment, enabling patient‑controlled health data access and transaction models across pharmacy, medical, laboratory and wearable settings.
According to Datavault AI, it will receive common shares equal to about 19.9% of DataMEDS common stock, instead of preferred shares, once previously disclosed transactions with Scilex, EOS Technology Holdings and HealthBridge Advisors/HighBridge close. The share issuance, expected to be recognized as revenue upon issuance, remains subject to acquisition of two QOLPOM intellectual property portfolios and a controlling interest in Tollo Health. DataMEDS recently rebranded from Wellgistics Health, began trading under ‘MEDS’ on July 22, 2026, and plans a dividend of 50 Dream Bowl Meme Coin tokens per common share owned as of an August 7, 2026 record date, subject to its discretion.